Literature DB >> 212641

Composition of bronchoalveolar lavage effluents from patients with pulmonary alveolar proteinosis.

G E Hook, D Y Bell, L B Gilmore, D Nadeau, M J Reasor, F A Talley.   

Abstract

The lungs of patients with pulmonary alveolar proteinosis were lavaged with saline. The lavage effluents were examined for the presence of unusual components which might be considered characteristic of the disease. Soluble proteins were resolved by electrophoresis on polyacrylamide linear gradient (2.5 to 27 per cent acrylamide) gel slabs and compared with proteins found in the patients' sera and lavage effluents from nondiseased human lungs. Many proteins in lavage effluents from both diseased and nondiseased lungs appeared similar to those found in serum. Several proteins from diseased lungs were not present in serum nor lavage effluents from nondiseased lungs. A number of proteins present in lavage effluents from nondiseased lungs appeared to be absent from lungs with alveolar proteinosis. Particulate components of lavage effluents from diseased and normal lungs were examined and compared using the electron microscope. Many particulate components including degenerate and disintegrating cells, ultrastructurally abnormal alveolar macrophages, and myelin-like structures were present in lavage effluents from diseased lungs but absent from normal lungs. Much of the particulate material resembled cell debris. The insoluble accumulations present in the pulmonary alveoli and airways of patients with alveolar proteinosis do not come from serum leakage nor from hypersecretion of materials normally found in these regions of the lungs. The major insoluble components appear to arise from cellular disintegration and the extracellular formation of myelin-like structures.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 212641

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  11 in total

Review 1.  Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis.

Authors:  P L Shah; D Hansell; P R Lawson; K B Reid; C Morgan
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

Review 2.  Secondary alveolar proteinosis in cancer patients.

Authors:  S Ladeb; J Fleury-Feith; E Escudier; J Tran Van Nhieu; J F Bernaudin; C Cordonnier
Journal:  Support Care Cancer       Date:  1996-11       Impact factor: 3.603

3.  Release of lamellar bodies from alveolar type 2 cells.

Authors:  N F Johnson
Journal:  Thorax       Date:  1980-03       Impact factor: 9.139

4.  Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage.

Authors:  G W Hunninghake; J E Gadek; O Kawanami; V J Ferrans; R G Crystal
Journal:  Am J Pathol       Date:  1979-10       Impact factor: 4.307

5.  Human surfactant protein A with two distinct oligomeric structures which exhibit different capacities to interact with alveolar type II cells.

Authors:  A Hattori; Y Kuroki; H Sohma; Y Ogasawara; T Akino
Journal:  Biochem J       Date:  1996-08-01       Impact factor: 3.857

6.  Classification and morphometric quantitation of insoluble materials from the lungs of patients with alveolar proteinosis.

Authors:  L B Gilmore; F A Talley; G E Hook
Journal:  Am J Pathol       Date:  1988-11       Impact factor: 4.307

7.  Surfactant protein D. Increased accumulation in silica-induced pulmonary lipoproteinosis.

Authors:  E Crouch; A Persson; D Chang; D Parghi
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

8.  Structural characteristics and intermolecular organization of human pulmonary-surfactant-associated proteins.

Authors:  S W Crawford; R P Mecham; H Sage
Journal:  Biochem J       Date:  1986-11-15       Impact factor: 3.857

9.  Accumulation of surfactant protein D in human pulmonary alveolar proteinosis.

Authors:  E Crouch; A Persson; D Chang
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

Review 10.  The pulmonary extracellular lining.

Authors:  G George; G E Hook
Journal:  Environ Health Perspect       Date:  1984-04       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.